BC Innovations | Mar 21, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Chronic obstructive pulmonary disease (COPD) In vitro and cell culture studies identified a dual-acting PDE-4 inhibitor/ ADRB2 agonist that could help treat COPD. In in vitro activity assays, a quinolone analog conjugated to a...
BC Week In Review | Oct 29, 2012
Clinical News

CHF 6001: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in about 74 healthy volunteers showed that single and repeated ascending-doses of up to 2,000 µg inhaled CHF 6001 for 7 days were well tolerated, including with respect...
Items per page:
1 - 2 of 2